Pinealon

Sometimes called EDR after its three building-block amino acids, Pinealon is made in a lab and comes out of a Russian research effort into short peptides known as bioregulators. Researchers propose it works by an unusual route for a peptide this small, entering nerve cells and interacting directly with DNA, and have studied it mainly in rodent and cell models of brain injury and cognitive aging.

What it is

Built from three amino acids in the sequence glutamic acid, aspartic acid, and arginine, Pinealon ranks among the tiniest peptides researchers in this area have looked at. It belongs to a family of short bioregulator peptides developed as part of the same Russian research program that produced several other tripeptides studied for different organ systems.

Unlike peptides that act mainly by binding a receptor on the outside of a cell, researchers studying Pinealon report that it slips inside the cell's nucleus and interacts with DNA there, which they propose changes gene activity related to nerve-cell protection and aging. This proposed mechanism is described in the papers reviewed for this entry as unusual and not yet mapped down to a specific receptor.

How it is studied

The evidence reviewed for Pinealon comes from a mouse model of Alzheimer's-like brain changes, a rat study comparing several amounts on a learning task, and a laboratory cell study looking at oxidative stress and cell-division markers. No human clinical trial of Pinealon has been published in the sources reviewed for this entry.

What studies report

A review of laboratory and animal studies on Pinealon reports that it slows the loss of small nerve-cell connections called dendritic spines in brain-cell cultures from mice with Alzheimer's- and Huntington's-like changes, and proposes that it does this partly by changing activity in a cell-signaling pathway called MAPK/ERK and by lowering markers tied to cell self-destruction. [1]
In a rat study using the Morris water maze, a standard spatial-learning test, Pinealon improved learning performance in both young and old rats, doing somewhat better than a comparison peptide from the same research program, alongside changes in caspase-3, a protein tied to cell self-destruction, in the brain. [2]
In a laboratory cell study, lower concentrations of the peptide reduced markers of oxidative stress and cell death, while higher concentrations were linked to changes tied to how the cells grow and divide, suggesting the effect depends on how much peptide the cells were exposed to. [3]

What is not known

Almost every study behind Pinealon traces back to one lab, a Russian institute in St. Petersburg devoted to aging and bioregulation science, so independent replication is limited. A specific claim reported in some secondary summaries, that a single optimal low amount of Pinealon raises NMDA receptor levels in the hippocampus during a study comparing several amounts, could not be traced to a findable primary paper and is not included here as a result. The proposed mechanism of directly entering the nucleus and binding DNA is described by the researchers themselves as not yet fully worked out at the level of how the peptide crosses the cell membrane, and no human clinical trial data exists in the sources reviewed.

Reported adverse findings

The animal and cell studies reviewed here focused on cognitive and cellular endpoints and did not report a formal toxicity or adverse-event profile for Pinealon. [1][2][3]

Regulatory status

None of the sources reviewed here show FDA clearance for Pinealon, nor has it received drug approval in Russia, where it was developed as a bioregulator peptide rather than a registered pharmaceutical.